489 related articles for article (PubMed ID: 8387607)
1. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer.
Cartei G; Cartei F; Cantone A; Causarano D; Genco G; Tobaldin A; Interlandi G; Giraldi T
J Natl Cancer Inst; 1993 May; 85(10):794-800. PubMed ID: 8387607
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
Cellerino R; Tummarello D; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
J Clin Oncol; 1991 Aug; 9(8):1453-61. PubMed ID: 1649267
[TBL] [Abstract][Full Text] [Related]
3. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy.
Thongprasert S; Sanguanmitra P; Juthapan W; Clinch J
Lung Cancer; 1999 Apr; 24(1):17-24. PubMed ID: 10403690
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
[TBL] [Abstract][Full Text] [Related]
5. High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study.
Gomm SA; Thatcher N; Cuthbert A; Chang J; Burmester H; Hall P; Carroll KB
Br J Cancer; 1991 Feb; 63(2):293-7. PubMed ID: 1847648
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group.
Feld R; Rubinstein L; Thomas PA
J Natl Cancer Inst; 1993 Feb; 85(4):299-306. PubMed ID: 8381187
[TBL] [Abstract][Full Text] [Related]
7. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
9. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
Ardizzoni A; Salvati F; Rosso R; Bruzzi P; Rubagotti A; Pennucci MC; Mariani GL; De Marinis F; Pallotta G; Antilli A
Cancer; 1993 Nov; 72(10):2929-35. PubMed ID: 8221559
[TBL] [Abstract][Full Text] [Related]
10. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group.
Gandara DR; Perez EA; Wold H; Caggiano V; Malec M; Ahn DK; Meyers F; Carlson RW
Cancer Chemother Pharmacol; 1990; 27(3):243-7. PubMed ID: 2176134
[TBL] [Abstract][Full Text] [Related]
11. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. An LCSG Trial.
Feld R; Rubinstein L; Thomas PA
Chest; 1994 Dec; 106(6 Suppl):307S-309S. PubMed ID: 7988250
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer.
Urban T; Bedin A; Baud M; Chouaid C; Febvre M; Lebeau B
Lung Cancer; 1996 Feb; 14(1):109-17. PubMed ID: 8696714
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with chemotherapy and neutron irradiation for limited non-small-cell lung cancer: a Southwest Oncology Group Study.
Livingston RB; Griffin BR; Higano CS; Laramore GE; Rivkin SE; Goldberg RS; Schulman SF
J Clin Oncol; 1987 Nov; 5(11):1716-24. PubMed ID: 2824705
[TBL] [Abstract][Full Text] [Related]
15. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
[TBL] [Abstract][Full Text] [Related]
16. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
17. Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated radiotherapy in split course for stage IIIA and stage IIIB non-small cell lung cancer: results of a phase I-II study by the GOTHA group. Group d'Oncologie Thoracique des Régions Alpines.
Alberto P; Mirimanoff RO; Mermillod B; Leyvraz S; Nagy-Mignotte H; Bolla M; Wellmann D; Moro D; Brambilla E
Eur J Cancer; 1995; 31A(3):342-8. PubMed ID: 7786599
[TBL] [Abstract][Full Text] [Related]
18. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer.
Sculier JP; Lafitte JJ; Berghmans T; Van Houtte P; Lecomte J; Thiriaux J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Paesmans M; Mommen P; Ninane V;
Ann Oncol; 2004 Mar; 15(3):399-409. PubMed ID: 14998841
[TBL] [Abstract][Full Text] [Related]
19. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
Dillman RO; Seagren SL; Propert KJ; Guerra J; Eaton WL; Perry MC; Carey RW; Frei EF; Green MR
N Engl J Med; 1990 Oct; 323(14):940-5. PubMed ID: 2169587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
